Ironwood Pharmaceuticals Total Liabilities 2010-2025 | IRWD

Ironwood Pharmaceuticals total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Ironwood Pharmaceuticals Annual Total Liabilities
(Millions of US $)
2024 $652
2023 $817
2022 $448
2021 $521
2020 $497
2019 $496
2018 $528
2017 $596
2016 $643
2015 $524
2014 $241
2013 $241
2012 $86
2011 $99
2010 $142
2009 $461
Ironwood Pharmaceuticals Quarterly Total Liabilities
(Millions of US $)
2025-03-31 $661
2024-12-31 $652
2024-09-30 $701
2024-06-30 $717
2024-03-31 $769
2023-12-31 $817
2023-09-30 $850
2023-06-30 $950
2023-03-31 $448
2022-12-31 $448
2022-09-30 $449
2022-06-30 $443
2022-03-31 $566
2021-12-31 $521
2021-09-30 $499
2021-06-30 $495
2021-03-31 $489
2020-12-31 $497
2020-09-30 $486
2020-06-30 $480
2020-03-31 $476
2019-12-31 $496
2019-09-30 $487
2019-06-30 $535
2019-03-31 $601
2018-12-31 $528
2018-09-30 $614
2018-06-30 $662
2018-03-31 $589
2017-12-31 $596
2017-09-30 $643
2017-06-30 $700
2017-03-31 $672
2016-12-31 $643
2016-09-30 $673
2016-06-30 $619
2016-03-31 $512
2015-12-31 $524
2015-09-30 $513
2015-06-30 $514
2015-03-31 $237
2014-12-31 $241
2014-09-30 $238
2014-06-30 $229
2014-03-31 $230
2013-12-31 $241
2013-09-30 $242
2013-06-30 $245
2013-03-31 $267
2012-12-31 $86
2012-09-30 $64
2012-06-30 $80
2012-03-31 $85
2011-12-31 $99
2011-09-30 $107
2011-06-30 $120
2011-03-31 $127
2010-12-31 $142
2010-09-30 $136
2010-06-30 $149
2010-03-31 $149
2009-12-31 $461
2009-09-30 $425
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.124B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $76.319B 28.63
Zoetis (ZTS) United States $66.158B 24.68
Takeda Pharmaceutical (TAK) Japan $45.915B 9.13
Daiichi Sankyo, - (DSNKY) Japan $45.464B 23.30
BeOne Medicines - (ONC) Cayman Islands $32.283B 0.00
Sandoz Group AG (SDZNY) Switzerland $25.049B 0.00
Summit Therapeutics (SMMT) United States $19.458B 0.00
Merck (MKKGY) Germany $16.692B 12.23
Shionogi (SGIOY) Japan $14.207B 14.23
United Therapeutics (UTHR) United States $13.172B 11.65
Neurocrine Biosciences (NBIX) United States $13.065B 44.75
Orion OYJ (ORINY) Finland $10.973B 26.45
IPSEN (IPSEY) France $10.477B 0.00
Stevanato Group S.p.A (STVN) Italy $7.541B 46.11
Corcept Therapeutics (CORT) United States $7.514B 61.09
Madrigal Pharmaceuticals (MDGL) United States $7.419B 0.00
Grifols, S.A (GRFS) Spain $6.834B 0.00
Ionis Pharmaceuticals (IONS) United States $6.646B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.214B 15.86
Soleno Therapeutics (SLNO) United States $4.394B 0.00
Hypermarcas (HYPMY) Brazil $3.056B 20.10
Crinetics Pharmaceuticals (CRNX) United States $2.913B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.565B 8.99
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.498B 13.51
NewAmsterdam Pharma (NAMS) Netherlands $2.492B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.095B 0.00
Ocular Therapeutix (OCUL) United States $1.805B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.802B 0.00
ARS Pharmaceuticals (SPRY) United States $1.760B 0.00
Endo (NDOI) United States $1.606B 0.00
Evotec AG (EVO) Germany $1.513B 0.00
Harrow (HROW) United States $1.317B 0.00
Guardian Pharmacy Services (GRDN) United States $1.283B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.166B 23.32
Enliven Therapeutics (ELVN) United States $1.112B 0.00
Ardelyx (ARDX) United States $1.055B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.048B 0.00
Dyne Therapeutics (DYN) United States $1.025B 0.00
Akebia Therapeutics (AKBA) United States $1.014B 0.00
Collegium Pharmaceutical (COLL) United States $1.003B 5.41
Verve Therapeutics (VERV) United States $0.973B 0.00
ProKidney (PROK) United States $0.922B 0.00
Xeris Biopharma Holdings (XERS) United States $0.799B 0.00
Cronos Group (CRON) Canada $0.775B 0.00
KalVista Pharmaceuticals (KALV) United States $0.769B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.743B 0.00
Zevra Therapeutics (ZVRA) United States $0.660B 0.00
Xencor (XNCR) United States $0.638B 0.00
Relay Therapeutics (RLAY) United States $0.600B 0.00
Elite Pharmaceuticals (ELTP) United States $0.599B 0.00
USANA Health Sciences (USNA) United States $0.565B 12.29
Theravance Biopharma (TBPH) United States $0.563B 0.00
Organogenesis (ORGO) United States $0.554B 0.00
Oruka Therapeutics (ORKA) United States $0.544B 0.00
Bioventus (BVS) United States $0.514B 13.04
Tourmaline Bio (TRML) United States $0.475B 0.00
Siga Technologies (SIGA) United States $0.472B 9.87
Aquestive Therapeutics (AQST) United States $0.417B 0.00
Savara (SVRA) United States $0.391B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.345B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.336B 9.08
Altimmune (ALT) United States $0.331B 0.00
Aldeyra Therapeutics (ALDX) United States $0.323B 0.00
Nektar Therapeutics (NKTR) United States $0.309B 0.00
Heron Therapeutics (HRTX) United States $0.294B 0.00
AleAnna (ANNA) United States $0.292B 0.00
Nature's Sunshine Products (NATR) United States $0.275B 25.20
Nanobiotix S.A (NBTX) France $0.250B 0.00
OmniAb (OABI) United States $0.238B 0.00
Esperion Therapeutics (ESPR) United States $0.232B 0.00
MediWound (MDWD) Israel $0.221B 0.00
Larimar Therapeutics (LRMR) United States $0.206B 0.00
4D Molecular Therapeutics (FDMT) United States $0.195B 0.00
China SXT Pharmaceuticals (SXTC) China $0.191B 0.00
Galectin Therapeutics (GALT) United States $0.177B 0.00
Aclaris Therapeutics (ACRS) United States $0.174B 0.00
Profound Medical (PROF) Canada $0.170B 0.00
Journey Medical (DERM) United States $0.168B 0.00
Liminatus Pharma (LIMN) United States $0.141B 0.00
Lexeo Therapeutics (LXEO) United States $0.138B 0.00
Lyell Immunopharma (LYEL) United States $0.137B 0.00
Inhibikase Therapeutics (IKT) United States $0.137B 0.00
Avita Medical (RCEL) United States $0.137B 0.00
Korro Bio (KRRO) United States $0.128B 0.00
Protara Therapeutics (TARA) United States $0.119B 0.00
Champions Oncology (CSBR) United States $0.111B 18.20
Innate Pharma SA (IPHYF) France $0.110B 0.00
Cassava Sciences (SAVA) United States $0.107B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.104B 0.00
VAXART, INC (VXRT) United States $0.101B 0.00
Cardiol Therapeutics (CRDL) Canada $0.098B 0.00
Achieve Life Sciences (ACHV) Canada $0.093B 0.00
Vivani Medical (VANI) United States $0.092B 0.00
Nutriband (NTRB) United States $0.090B 0.00
Fractyl Health (GUTS) United States $0.088B 0.00
ESSA Pharma (EPIX) Canada $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.083B 0.00
Context Therapeutics (CNTX) United States $0.080B 0.00
Dominari Holdings (DOMH) United States $0.079B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.076B 0.00
Metagenomi (MGX) United States $0.074B 0.00
Surrozen (SRZN) United States $0.073B 0.00
Wellgistics Health (WGRX) United States $0.073B 0.00
Rafael Holdings (RFL) United States $0.072B 0.00
Pyxis Oncology (PYXS) United States $0.070B 0.00
PMV Pharmaceuticals (PMVP) United States $0.069B 0.00
Telomir Pharmaceuticals (TELO) United States $0.068B 0.00
Avalo Therapeutics (AVTX) United States $0.068B 0.00
Assertio Holdings (ASRT) United States $0.064B 0.00
Inotiv (NOTV) United States $0.060B 0.00
Klotho Neurosciences (KLTO) United States $0.059B 0.00
Unicycive Therapeutics (UNCY) United States $0.056B 0.00
ElectroCore (ECOR) United States $0.054B 0.00
Jupiter Neurosciences (JUNS) United States $0.054B 0.00
NRx Pharmaceuticals (NRXP) United States $0.051B 0.00
Century Therapeutics (IPSC) United States $0.050B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.048B 35.78
Gain Therapeutics (GANX) United States $0.048B 0.00
Prelude Therapeutics (PRLD) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.043B 0.00
Acrivon Therapeutics (ACRV) United States $0.042B 0.00
PolyPid (PYPD) Israel $0.037B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
Vivos Therapeutics (VVOS) United States $0.034B 0.00
Karyopharm Therapeutics (KPTI) United States $0.033B 0.00
FibroGen (FGEN) United States $0.031B 0.00
SCYNEXIS (SCYX) United States $0.028B 0.00
Enlivex Therapeutics (ENLV) Israel $0.028B 0.00
Scienture Holdings (SCNX) United States $0.028B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.019B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.019B 0.00
Relmada Therapeutics (RLMD) United States $0.019B 0.00
BioLineRx (BLRX) Israel $0.019B 0.00
Plus Therapeutics (PSTV) United States $0.019B 0.00
Incannex Healthcare (IXHL) Australia $0.018B 0.00
VYNE Therapeutics (VYNE) United States $0.018B 0.00
BioVie (BIVI) United States $0.017B 0.00
Lipocine (LPCN) United States $0.017B 0.00
DURECT (DRRX) United States $0.017B 0.00
Carisma Therapeutics (CARM) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
CASI Pharmaceuticals (CASI) China $0.016B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
Mannatech (MTEX) United States $0.015B 0.00
Ernexa Therapeutics (ERNA) United States $0.015B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Ainos (AIMD) United States $0.012B 0.00
Lyra Therapeutics (LYRA) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Biomerica (BMRA) United States $0.009B 0.00
Aptorum Group (APM) United Kingdom $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Talphera (TLPH) United States $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
SHINECO (SISI) China $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.001B 0.00
TNF Pharmaceuticals (TNFA) United States $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Indivior (INDV) United States $0.000B 9.36
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 2.43
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00